We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology
Product News

Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology

Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology
Product News

Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology

CoaguChek® Vantus system

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Roche introduces first self-testing device for Warfarin monitoring with built in Bluetooth® technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche announced today plans to launch the CoaguChek Vantus system, the first self-testing device for coagulation monitoring with built in Bluetooth technology. Patient self-testing with the Bluetooth-enabled CoaguChek Vantus system allows for a new level of patient monitoring. Patients can use their tablet or smartphone with a compatible app to send their results automatically via wireless connectivity which enables healthcare providers to receive patient INR results rapidly and accurately, while also reducing visits to the lab.

For the patient, this means no manual test results entry, and no time spent waiting on the phone to report their results. For the healthcare provider, this means reliable results they can count on sent wirelessly and directly from the patient's meter to their office and a service provider, such as CoaguChek Patient Services who manage patient training and result reporting.

"As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important," said Dr. Alan Wright, Chief Medical Officer, Roche Diagnostics. "This innovative technology sets the standard in coagulation monitoring by providing high quality, convenient testing, while optimizing the patient result reporting workflow.

Self-testing can enable patients to test more conveniently, which may improve their time in the target INR range set by their doctor as compared to in-office or lab testing. And when compared with lab testing, patient self-testing has been correlated with fewer thromboembolic events.

Self-testing provides patients with tools and flexibility to be more engaged in their therapy and this supports better compliance. In addition, self-testing can also help patients stay connected to their doctor, who can quickly receive the results following the patient's self-test.

The CoaguChek Vantus system is expected to be commercially available in the United States in the Summer of 2018.
Advertisement